Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 286, Issue 1 49-1, 2004, Pages

  Storr, M ^a   Sibaev, A ^a   Marsicano, G ^b   Lutz, B ^b   Schusdziarra, V ^a   Timmermans, J P ^c   Allescher, H D ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Anandamide; Cannabinoid receptor type 1 deficient mice; Excitatory junction potential; Inhibitory junction potential; Intracellular recording

Indexed keywords

ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; NITRIC OXIDE SYNTHASE; RIMONABANT; UNCLASSIFIED DRUG; [2,3 DIHYDRO 5 METHYL 3 (4 MORPHOLINYLMETHYL)PYRROLO[1,2,3 DE] 1,4 BENZOXAZIN 6 YL] 1 NAPHTHALENYLMETHANONE;

ANIMAL TISSUE; ARTICLE; CHOLINERGIC TRANSMISSION; ELECTROSTIMULATION; EXCITATORY JUNCTION POTENTIAL; FEMALE; INTESTINE INNERVATION; MALE; MEMBRANE STEADY POTENTIAL; MOUSE; MYENTERIC PLEXUS; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SMOOTH MUSCLE FIBER MEMBRANE POTENTIAL; WILD TYPE;

EID: 0347357999     PISSN: 01931857     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpgi.00148.2003     Document Type: Article

References (35)

1. Adami M, Frati P, Bertini S, Kulkarni-Narla A, Brown DR, De Caro G, Coruzzi G, and Soldani G. Gastric antisecretory role and immunohistochemical localization of cannabinoid receptors in the rat stomach. Br J Pharmacol 135: 1598-1606, 2002.
2. Begg M, Dale N, Llaudet E, Molleman A, and Parsons ME. Modulation of the release of endogenous adenosine by cannabinoids in the myenteric plexus-longidtudinal muscle preparation of the guinea-pig ileum. Br J Pharmacol 137: 1298-1304, 2002.
3. Brouns I, Van Nassauw L, Van Genechten J, Majewski M, Scheuermann DW, Timmermans JP, and Adraiensen D. Triple immunofluorescence staining method with antibodies raised in the same species to study the complex innervation pattern of intrapulmonary chemoreceptors. J Histochem Cytochem 50: 575-582, 2002.
4. Calignano A, La Rana G, Mikriyanis A, Lin SA, Beltramo M, and Piomelli D. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. Eur J Pharmacol 340: R7-R8, 1997.
5. Casu MA, Porcella A, Ruiu S, Saba P, Marchese G, Carai MAM, Reali R, Gessa GL, and Palli L. Differential distribution of functional cannabinoid CB1 receptors in the mouse gastrointestinal tract. Eur J Pharmacol 459: 97-105, 2003.
6. Coutts AA, Irving AJ, Mackie K, Pertwee RG, and Anavi-Goffer S. Localisation of cannabinoid CB1 receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol 448: 410-422, 2002.
7. Coutts AA and Pertwee RG. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br J Pharmacol 121: 1557-1566, 1997.
8. 2+ and cAMP. Can J Physiol Pharmacol 76: 340-346, 1998.
9. Di Carlo G and Izzo AA. Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opin Investig Drugs 12: 39-49, 2003.
10. Dinh TP, Freund TF, and Piomelli D. A role for monoglyceride lipase in 2-arachidonylglycerol inactivation. Chem Phys Lipids 121: 149-158, 2002.
11. Franck H, Sweeney KM, Sanders KM, and Shuttleworth CW. Effects of a novel guanylate cyclase inhibitor on nitric oxide-dependent inhibitory neurotransmission in canine proximal colon. Br J Pharmacol 122: 1223-1229, 1997.
12. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, and Pertwee RG. International Union of Pharmacology. XXVII classification of cannabinoid receptors. Pharmacol Rev 54: 161-202, 2002.
13. 1 receptors. Br J Pharmacol 124: 1363-1368, 1998.
14. Izzo AA, Mascolo N, and Capasso F. The gastrointestinal pharmacology of cannabinoids. Curr Opin Pharmacol 1: 597-603, 2001.
15. Izzo AA, Pinto L, Borrelli F, Capasso R, Mascolo N, and Capasso F. Central and peripheral cannabinoid modulation of gastrointestinal transit in physiological states or during the diarrhoea induced by croton oil. Br J Pharmacol 129: 1627-1632, 2000.
16. Kathmann M, Bauer U, Schlicker M, and Gothert M. Cannabinoid CB1 receptor-mediated inhibition of NMDA-and kainate-stimulated noradrenaline and dopamine release in the brain. Naunyn Schmiedebergs Arch Pharmacol 359: 466-470, 1999.
17. Kathmann M, Weber B, Zimmer A, and Schlicker E. Enhanced acetylcholine release in the hippocampus of cannabinoid CB(1) receptor-deficient mice. Br J Pharmacol 132: 1169-1173, 2003.
18. Kulkarni-Narla A and Brown DR. Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res 302: 73-80, 2000.
19. Kulkarni-Narla A and Brown DR. Opioid, cannabinoid and vanilloid receptor localisation on porcine cultured myenteric neurons. Neurosci Lett 308: 153-156, 2001.
20. Lopez-Redondo F, Lees GM, and Pertwee RG. Effects of cannabinoid receptor ligands on electrophysiological properties of myenteric neurons of the guinea-pig ileum. Br J Pharmacol 122: 330-334, 1997.
21. Lutz B. Molecular biology of cannabinoid receptors. Prostaglandins, Leukot Essent Fatty Acids 66: 123-142, 2002.
22. Manara L, Croci T, Guagnini F, Rinaldi-Carmona M, Maffrand JP, Le Fur G, Mukenge S, and Feria G. Functional assessment of neuronal cannabinoid receptors in the muscular layers of human ileum and colon. Dig Liver Dis 34: 262-269, 2002.
23. Mancinelli R, Fabrizi A, Del Monaco S, Azzena GB, Variu R, Colombo GC, and Gessa GL. Inhibition of peristaltic activity by cannabinoids in the isolated distal colon of mouse. Life Sci 69: 101-111, 2001.
24. Mang CF, Erbelding D, and Kilbinger H. Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-CB1 cannabinoid receptors. Br J Pharmacol 134: 161-167, 2001.
25. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgänsberger W, Di Marzo V, and Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. Nature 418: 530-534, 2001.
26. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, and Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564, 1990.
27. 2 receptors. Pharmacol Ther 74: 129-180, 1997.
28. Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut 48: 859-867, 2001.
29. Pinto L, Izzo AA, Cascio MG, Bisogno T, Hospodar-Scott K, Brown DR, Mascolo N, Di Marzo V, and Capasso F. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 123: 227-234, 2002.
30. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, and Felder CC. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301: 1020-1024, 2002.
31. Rinaldi-Carmona M, Barth F, Heaulme M, Alonso R, Shire D, Congy C, Soubrie P, Breliere JC, and Le Fur G. Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 56: 1941-1947, 1995.
32. Schlicker E and Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 22: 565-572, 2001.
33. Shuttleworth CW, Conlon SB, and Sanders KM. Regulation of citrulline recycling in nitric oxide-dependent neurotransmission in the murine proximal colon. Br J Pharmacol 120: 707-713, 1997.
34. Storr M, Gaffal E, Saur D, Schusdziarra V, and Allescher HD. Influence of cannabinoids on neurotransmission in rat gastric fundus. Can J Physiol Pharmacol 80: 67-76, 2002.
35. Ward SM, Dalziel HH, Thornbury KD, Westfall DP, and Sanders KM. Nonadrenergic, noncholinergic inhibition and rebound excitation in canine colon depend on nitric oxide. Am J Physiol Gastrointest Liver Physiol 262: G237-G243, 1992.